Considerations for reporting variants in novel candidate genes identified during clinical genomic testing
- PMID: 38944749
- DOI: 10.1016/j.gim.2024.101199
Considerations for reporting variants in novel candidate genes identified during clinical genomic testing
Abstract
Since the first novel gene discovery for a Mendelian condition was made via exome sequencing (ES), the rapid increase in the number of genes known to underlie Mendelian conditions coupled with the adoption of exome (and more recently, genome) sequencing by diagnostic testing labs has changed the landscape of genomic testing for rare disease. Specifically, many individuals suspected to have a Mendelian condition are now routinely offered clinical ES. This commonly results in a precise genetic diagnosis but frequently overlooks the identification of novel candidate genes. Such candidates are also less likely to be identified in the absence of large-scale gene discovery research programs. Accordingly, clinical laboratories have both the opportunity, and some might argue a responsibility, to contribute to novel gene discovery which should in turn increase the diagnostic yield for many conditions. However, clinical diagnostic laboratories must necessarily balance priorities for throughput, turnaround time, cost efficiency, clinician preferences, and regulatory constraints, and often do not have the infrastructure or resources to effectively participate in either clinical translational or basic genome science research efforts. For these and other reasons, many laboratories have historically refrained from broadly sharing potentially pathogenic variants in novel genes via networks like Matchmaker Exchange, much less reporting such results to ordering providers. Efforts to report such results are further complicated by a lack of guidelines for clinical reporting and interpretation of variants in novel candidate genes. Nevertheless, there are myriad benefits for many stakeholders, including patients/families, clinicians, researchers, if clinical laboratories systematically and routinely identify, share, and report novel candidate genes. To facilitate this change in practice, we developed criteria for triaging, sharing, and reporting novel candidate genes that are most likely to be promptly validated as underlying a Mendelian condition and translated to use in clinical settings.
Copyright © 2024. Published by Elsevier Inc.
Update of
-
Considerations for reporting variants in novel candidate genes identified during clinical genomic testing.bioRxiv [Preprint]. 2024 Jun 21:2024.02.05.579012. doi: 10.1101/2024.02.05.579012. bioRxiv. 2024. Update in: Genet Med. 2024 Jun 26:101199. doi: 10.1016/j.gim.2024.101199. PMID: 38370830 Free PMC article. Updated. Preprint.
Similar articles
-
Considerations for reporting variants in novel candidate genes identified during clinical genomic testing.bioRxiv [Preprint]. 2024 Jun 21:2024.02.05.579012. doi: 10.1101/2024.02.05.579012. bioRxiv. 2024. Update in: Genet Med. 2024 Jun 26:101199. doi: 10.1016/j.gim.2024.101199. PMID: 38370830 Free PMC article. Updated. Preprint.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Diagnostic testing laboratories are valuable partners for disease gene discovery: 5-year experience with GeneMatcher.Hum Mutat. 2022 Jun;43(6):772-781. doi: 10.1002/humu.24342. Epub 2022 Mar 2. Hum Mutat. 2022. PMID: 35143109 Free PMC article.
-
Genomic Data Sharing for Novel Mendelian Disease Gene Discovery: The Matchmaker Exchange.Annu Rev Genomics Hum Genet. 2020 Aug 31;21:305-326. doi: 10.1146/annurev-genom-083118-014915. Epub 2020 Apr 27. Annu Rev Genomics Hum Genet. 2020. PMID: 32339034 Review.
-
Centers for Mendelian Genomics: A decade of facilitating gene discovery.Genet Med. 2022 Apr;24(4):784-797. doi: 10.1016/j.gim.2021.12.005. Epub 2022 Feb 9. Genet Med. 2022. PMID: 35148959 Free PMC article. Review.
LinkOut - more resources
Full Text Sources